Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunome Inc (NQ: IMNM )

14.06 +0.24 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome Inc

< Previous 1 2 3 Next >
Immunome Appoints Sandra M. Swain to Board of Directors
From Immunome
Via Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
From Immunome, Inc.
Via Business Wire
Immunome Inc. (NASDAQ: IMNM) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Participate in the Leerink Partners Global Biopharma Conference
From Immunome, Inc.
Via Business Wire
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Immunome, Inc.
Via Business Wire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Immunome, Inc.
Via Business Wire
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
Immunome Appoints Phil Roberts as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Carol A. Schafer to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
From Immunome, Inc.
Via Business Wire
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Immunome to Present at the Stifel 2023 Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
From Immunome, Inc.
Via Business Wire
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2023 Financial Results
From Immunome, Inc.
Via Business Wire
IMNM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Immunome, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
Via Spotlight Growth
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.